PharmEasy-owned Thyrocare Technologies reported a 128% year-on-year jump in Q4 FY26 consolidated net profit to Rs 48.7 crore, driven by operating leverage and volume growth. Revenue from operations rose 20% to Rs 224 crore. Tests processed surged 29% to 5.9 crore, while margins improved. The company also launched advanced allergy testing and entered genomics with NIPT.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
